Diversion Quarterly Q4 2020

Kit Check is sharing data from its Bluesight™ for Controlled Substances platform on a quarterly basis to provide insight into the types of diversions and investigations that may be occurring in hospital pharmacies. The following information is as of September 30, 2020. Data was pulled from health systems across the United States.

Commentary from the CEO

“With the COVID-19 pandemic worsening America’s opioid crisis, it’s more crucial than ever for hospitals to keep a sharp eye on drug diversion,” said Kevin MacDonald, CEO of Kit Check. “Tracking variances is imperative in fighting the opioid epidemic as a second COVID-19 wave looms and an increasing number of employees are flagged for exhibiting anomalous activity. Bluesight for Controlled Substances has reviewed more than 15 million cases and continues to provide valuable insights into drug diversion.”

Download the latest information about our suite of medication intelligence products by using the button below.